Biplane US-Guided Real-Time Volumetric Target Pose Estimation Method for Theragnostic HIFU System

Joonho Seo,N. Koizumi,T. Funamoto,N. Sugita,K. Yoshinaka,A. Nomiya,Y. Homma,Y. Matsumoto,M. Mitsuishi

DOI: https://doi.org/10.20965/jrm.2011.p0400

2011-06-20

Abstract:

What problem does this paper attempt to address?

Safety and immunogenicity of the Rotavac and Rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants: a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial

Suman Kanungo,Pranab Chatterjee,Ashish Bavdekar,Manoj Murhekar,Sudhir Babji,Richa Garg,Sandip Samanta,Ranjan K Nandy,Anand Kawade,Kangusamy Boopathi,Kaliaperumal Kanagasabai,Vineet Kumar Kamal,Velusamy Saravana Kumar,Nivedita Gupta,Shanta Dutta

DOI: https://doi.org/10.1016/S1473-3099(22)00161-X

Abstract:Background: Rotavirus is the leading cause of severe dehydrating gastroenteritis among children younger than 5 years in low-income and middle-income countries. Two vaccines-Rotavac and Rotasiil-are used in routine immunisation in India. The safety and immunogenicity of these vaccines administered in a mixed regimen is not documented. We therefore aimed to compare the safety and seroresponse of recipients of a mixed regimen versus a single regimen. Methods: We did a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial at two sites in India. We recruited healthy infants aged 6-8 weeks. Infants with systemic disorders, weight-for-height Z scores of less than minus three SDs, or a history of persistent diarrhoea were excluded. Eligible infants were randomly allocated to six groups in equal numbers to receive either the single vaccine regimen (ie, Rotavac-Rotavac-Rotavac [group 1] or Rotasiil-Rotasiil-Rotasiil [group 2]) or the mixed vaccine regimen (ie, Rotavac-Rotasiil-Rotavac [group 3], Rotasiil-Rotavac-Rotasiil [group 4], Rotavac-Rotasiil-Rotasiil [group 5], or Rotasiil-Rotavac-Rotavac [group 6]). Randomisation was done using an online software by site in blocks of at least 12. The primary outcome was seroresponse to rotavirus vaccine, measured using rotavirus-specific serum IgA antibodies 4 weeks after the third dose. The seroresponse rates were compared between recipients of the four mixed vaccine regimens (consisting of various combinations of Rotavac and Rotasiil) with recipients of the single vaccine regimens (consisting of Rotavac or Rotasiil only for all three doses). The non-inferiority margin was set at 10%. Safety follow-ups were done for the duration of study participation. This trial was registered with the Clinical Trials Registry India, number CTRI/2018/08/015317. Findings: Between March 25, 2019, and Jan 15, 2020, a total of 1979 eligible infants were randomly assigned to receive a single vaccine regimen (n=659; 329 in group 1 and 330 in group 2) or a mixed vaccine regimen (n=1320; 329 each in groups 3 and 4, and 331 each in groups 5 and 6). All eligible participants received the first dose, 1925 (97·3%) of 1979 received the second dose, and 1894 (95·7%) received all three doses of vaccine. 1852 (93·6%) of 1979 participants completed the follow-up. The immunogenicity analysis consisted of 1839 infants (1238 [67·3%] in the mixed vaccine regimen and 601 [32·7%] in the single vaccine regimen; 13 samples were insufficient in quantity) who completed vaccination and provided post-vaccination sera. The seroresponse rate in the mixed vaccine regimen group (33·5% [95% CI 30·9-36·2]) was non-inferior compared with the single vaccine regimen group (29·6% [26·1-33·4]); the seroresponse rate difference was 3·9% (95% CI -0·7 to 8·3). The proportion of participants with any type of solicited adverse events was 90·9% (95% CI 88·4-93·0) in the single vaccine regimen group and 91·1% (89·5-92·6) in the mixed vaccine regimen group. No vaccine-related serious adverse events or intussusception were reported during the study. Interpretation: Rotavac and Rotasiil can be safely used in an interchangeable manner for routine immunisation since the seroresponse was non-inferior in the mixed vaccine regimen compared with the single vaccine regimen. These results allow for flexibility in administering the vaccines, helping to overcome vaccine shortages and supply chain issues, and targeting migrant populations easily. Funding: Ministry of Health and Family Welfare, Government of India. Translation: For the Hindi translation of the abstract see Supplementary Materials section.
Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial

K. Zaman,Jessica A. Fleming,John C. Victor,Mohammad Yunus,Tajul Islam A. Bari,Tasnim Azim,Mustafizur Rahman,Syed Mohammad Niaz Mowla,William J. Bellini,Monica McNeal,Joseph P. Icenogle,Ben Lopman,Umesh Parashar,Margaret M. Cortese,A. Duncan Steele,Kathleen M. Neuzil

DOI: https://doi.org/10.1093/infdis/jiw024

2016-01-27

Abstract:BACKGROUND: The burden of rotavirus morbidity and mortality is high in children aged <5 years in developing countries, and evaluations indicate waning protection from rotavirus immunization in the second year. An additional dose of rotavirus vaccine may enhance the immune response and lengthen the period of protection against disease, but coadministration of this dose should not interfere with immune responses to concurrently given vaccines.METHODS: A total of 480 9-month-old participants from Matlab, Bangladesh, were enrolled in a study with a primary objective to establish noninferiority of concomitant administration of measles-rubella vaccine (MR) and a third dose of human rotavirus vaccine (HRV; MR + HRV), compared with MR given alone. Secondary objectives included noninferiority of rubella antibody seroconversion and evaluating rotavirus IgA/IgG seroresponses in MR + HRV recipients.RESULTS: Two months after vaccination, 75.3% and 74.3% of MR + HRV and MR recipients, respectively, had seroprotective levels of measles virus antibodies; 100.0% and 99.6%, respectively, showed anti-rubella virus immunoglobulin G (IgG) seroprotection. In the MR + HRV group, antirotavirus immunoglobulin A and IgG seropositivity frequencies before vaccination (52.7% and 66.3%, respectively) increased to 69.6% and 88.3% after vaccination.CONCLUSIONS: Vaccine-induced measles and rubella antibody responses are not negatively affected by concomitant administration of HRV. The HRV dose increases antirotavirus serum antibody titers and the proportion of infants with detectable antirotavirus antibody.CLINICAL TRIALS REGISTRATION: NCT01700621.

immunology,infectious diseases,microbiology
Angiographically occult vascular malformations in childhood.

E. El-Gohary,T. Tomita,F. Gutierrez,David G. McLone

DOI: https://doi.org/10.1227/00006123-198705000-00014

IF: 5.315

1987-05-01

Neurosurgery

Abstract:Five infants and children with angiographically occult vascular malformations of the brain detected by computed tomography (CT) are presented. Four malformations were located in the cerebral hemisphere, and one was in the brain stem. CT demonstrated high density lesions with little or no enhancement after infusion of the contrast material. The malformations were resected and histologically proven. All patients have done well. The pertinent literature is reviewed. These lesions are uncommon during infancy and childhood and mimic gliomas clinically and radiographically. The need for surgical extirpation of these lesions is stressed.
Immunogenicity of pentavalent rotavirus vaccine in Chinese infants

Zhaojun Mo,Xiao Ma,Peng Luo,Yi Mo,Susan S Kaplan,Qiong Shou,Minghuan Zheng,Darcy A Hille,Beth A Arnold,V260-024 Study Group,Xueyan Liao

DOI: https://doi.org/10.1016/j.vaccine.2019.02.018

IF: 4.169

2019-03-22

Vaccine

Abstract:Background: A phase III, randomized, double-blind, placebo-controlled clinical study was conducted in China to assess the efficacy, safety, and immunogenicity of the pentavalent rotavirus vaccine (RotaTeqTM, RV5) among Chinese infants. The efficacy and safety data have been previously reported. This report presents the immunogenicity data of the study. Methods: 4,040 infants aged 6-12 weeks were randomly assigned in a 1:1 ratio to receive 3 oral doses of RV5 or placebo. Trivalent oral poliovirus vaccine (tOPV) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP) were administered in a staggered-use (N = 3,240) or concomitant-use (N = 800) schedule. Immunogenicity of RV5 was evaluated in 800 participants (400 participants from each staggered- and concomitant-use immunogenicity subgroup). Geometric mean titers (GMTs) and seroresponse rates (≥3-fold rise from baseline to PD3) were measured for anti-rotavirus IgA in the staggered- and concomitant-use subgroups and measured for serum neutralizing antibodies (SNAs) to human rotavirus serotypes G1, G2, G3, G4, P1A[8] in the staggered-use subgroup. Immune responses to tOPV and DTaP co-administered with RV5 were also evaluated in the concomitant-use immunogenicity subgroup. (ClinicalTrials.gov registry: NCT02062385) RESULTS: The PD3 GMT and seroresponse rate of anti-rotavirus IgA were higher in the RV5 group (82.42 units/mL, 89.4%) compared to the placebo group (0.33 units/mL, 10.1%). Rotavirus type-specific SNA responses were also higher in the RV5 group compared to the placebo group. In the concomitant-use subgroup, the seroprotection rates of anti-poliovirus type 1, 2, 3 in the participants who received RV5 were non-inferior to those who received placebo, and the antibody responses to DTaP antigens were comparable between the two vaccination groups. Conclusions: RV5 was immunogenic in Chinese infants. Immune responses induced by tOPV and DTaP were not affected by the concomitant use of RV5.
Treatment refusal in anorexia nervosa.

E. Goldner

DOI: https://doi.org/10.1002/1098-108X(198905)8:3<297::AID-EAT2260080305>3.0.CO;2-H

1989-05-01

International Journal of Eating Disorders

Abstract:Individuals with anorexia nervosa often refuse treatment for the disorder. A subset of individuals vehemently reject medical and/or psychological therapy. Of these some may be temporarily denied the right to refuse treatment. The author reviews psychological and philosophical aspects of treatment refusal by individuals with anorexia nervosa. Psychodynamic and cognitive processes involved in refusal are discussed. The author identifies principles which assist in guiding the negotiation of treatment refusal in anorexia nervosa.
Immunogenicity of RV1 and RV5 vaccines administered in standard and interchangeable mixed schedules: a randomized, double-blind, non-inferiority clinical trial in Mexican infants

Mercedes Macías-Parra,Patricia Vidal-Vázquez,Jesús Reyna-Figueroa,Miguel Ángel Rodríguez-Weber,Hortensia Moreno-Macías,Inés Hernández-Benavides,Sofía Fortes-Gutiérrez,Vesta Louise Richardson,Paola Vázquez-Cárdenas

DOI: https://doi.org/10.3389/fpubh.2024.1356932

IF: 5.2

2024-02-23

Frontiers in Public Health

Abstract:Introduction: Rotavirus-associated diarrheal diseases significantly burden healthcare systems, particularly affecting infants under five years. Both RotarixTM (RV1) and RotaTeqTM (RV5) vaccines have been effective but have distinct application schedules and limited interchangeability data. This study aims to provide evidence on the immunogenicity, reactogenicity, and safety of mixed RV1-RV5 schedules compared to their standard counterparts. Methods: This randomized, double-blind study evaluated the non-inferiority in terms of immunogenicity of mixed rotavirus vaccine schedules compared to standard RV1 and RV5 schedules in a cohort of 1,498 healthy infants aged 6 to 10 weeks. Participants were randomly assigned to one of seven groups receiving various combinations of RV1, and RV5. Standard RV1 and RV5 schedules served as controls of immunogenicity, reactogenicity, and safety analysis. IgA antibody levels were measured from blood samples collected before the first dose and one month after the third dose. Non-inferiority was concluded if the reduction in seroresponse rate in the mixed schemes, compared to the standard highest responding scheme, did not exceed the non-inferiority margin of −0.10. Reactogenicity traits and adverse events were monitored for 30 days after each vaccination and analyzed on the entire cohort. Results: Out of the initial cohort, 1,365 infants completed the study. Immunogenicity analysis included 1,014 infants, considering IgA antibody titers ≥20 U/mL as seropositive. Mixed vaccine schedules demonstrated non-inferiority to standard schedules, with no significant differences in immunogenic response. Safety profiles were comparable across all groups, with no increased incidence of serious adverse events or intussusception. Conclusion: The study confirms that mixed rotavirus vaccine schedules are non-inferior to standard RV1 and RV5 regimens in terms of immunogenicity and safety. This finding supports the flexibility of rotavirus vaccination strategies, particularly in contexts of vaccine shortage or logistic constraints. These results contribute to the global effort to optimize rotavirus vaccination programs for broader and more effective pediatric coverage. Clinical trial registration : ClinicalTrials.gov, NCT02193061.

public, environmental & occupational health
Association of Rotavirus Vaccines With Reduction in Rotavirus Gastroenteritis in Children Younger Than 5 Years

Zi-Wei Sun,Yu Fu,Hai-Ling Lu,Rui-Xia Yang,Hemant Goyal,Ye Jiang,Hua-Guo Xu

DOI: https://doi.org/10.1001/jamapediatrics.2021.0347

2021-05-10

JAMA Pediatrics

Abstract:Question Is there a strong association of rotavirus vaccines and preventing rotavirus gastroenteritis (RVGE)?Findings Meta-analysis revealed that Rotarix and RotaTeq reduced RVGE in children younger than 5 years by 68.4% and 63.6%, respectively, and this was confirmed in case-control studies (65.3% and 72.8%, respectively). Adjusted indirect comparisons indicated no significant differences in the protection of Rotarix and RotaTeq; other rotavirus vaccines, including Rotavac, Rotasiil, and Lanzhou lamb rotavirus vaccine, also showed positive associations with reduced RVGE risk.Meaning The findings favor the worldwide introduction of rotavirus vaccines to prevent RVGE, but head-to-head comparisons are needed to compare the benefit and risk of different rotavirus vaccines.Importance Rotavirus vaccines have been introduced worldwide, and the clinical association of different rotavirus vaccines with reduction in rotavirus gastroenteritis (RVGE) after introduction are noteworthy.Objective To evaluate the comparative benefit, risk, and immunogenicity of different rotavirus vaccines by synthesizing randomized clinical trials (RCTs) and observational studies.Data Sources Relevant studies published in 4 databases: Embase, PubMed, the Cochrane Library, and Web of Science were searched until July 1, 2020, using search terms including "rotavirus" and "vaccin*."Study Selection Randomized clinical trials and cohort and case-control studies involving more than 100 children younger than 5 years that reported the effectiveness, safety, or immunogenicity of rotavirus vaccines were included.Data Extraction and Synthesis A random-effects model was used to calculate relative risks (RRs), odds ratios (ORs), risk differences, and 95% CIs. Adjusted indirect treatment comparison was performed to assess the differences in the protection of Rotarix and RotaTeq.Main Outcomes and Measures The primary outcomes were RVGE, severe RVGE, and RVGE hospitalization. Safety-associated outcomes involved serious adverse events, intussusception, and mortality.Results A meta-analysis of 20 RCTs and 38 case-control studies revealed that Rotarix (RV1) significantly reduced RVGE (RR, 0.316 [95% CI, 0.224-0.345]) and RVGE hospitalization risk (OR, 0.347 [95% CI, 0.279-0.432]) among children fully vaccinated; RotaTeq (RV5) had similar outcomes (RVGE: RR, 0.350 [95% CI, 0.275-0.445]; RVGE hospitalization risk: OR, 0.272 [95% CI, 0.197-0.376]). Rotavirus vaccines also demonstrated higher protection against severe RVGE. Additionally, no significant differences in the protection of RV1 and RV5 against rotavirus disease were noted in adjusted indirect comparisons. Moderate associations were found between reduced RVGE risk and Rotavac (RR, 0.664 [95% CI, 0.548-0.804]), Rotasiil (RR, 0.705 [95% CI, 0.605-0.821]), and Lanzhou lamb rotavirus vaccine (RR, 0.407 [95% CI, 0.332-0.499]). All rotavirus vaccines demonstrated no risk of serious adverse events. A positive correlation was also found between immunogenicity and vaccine protection (eg, association of RVGE with RV1: coefficient, −1.599; adjusted R2, 99.7%).Conclusions and Relevance The high protection and low risk of serious adverse events for rotavirus vaccines in children who were fully vaccinated emphasized the importance of worldwide introduction of rotavirus vaccination. Similar protection provided by Rotarix and RotaTeq relieves the pressure of vaccines selection for health care authorities.

medicine, general & internal
Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Coadministered With Measles, Yellow Fever, and Meningitis A Vaccines in 9-Month-Old Malian Infants

Fadima C Haidara,Milagritos D Tapia,Samba O Sow,Moussa Doumbia,Flanon Coulibaly,Fatoumata Diallo,Awa Traoré,Mamoudou Kodio,Corey L Kelly,Meagan Fitzpatrick,Karen Kotloff,John C Victor,Kathleen Neuzil

DOI: https://doi.org/10.1093/infdis/jiy215

2018-07-13

Abstract:Background: Rotavirus vaccines given to infants are safe and efficacious. A booster dose of rotavirus vaccine could extend protection into the second year of life in low-resource countries. Methods: We conducted an open-label, individual-randomized trial in Bamako, Mali. We assigned 600 infants aged 9-11 months to receive measles vaccine (MV), yellow fever vaccine (YFV), and meningococcal A conjugate vaccine (MenAV) with or without pentavalent rotavirus vaccine (PRV). We assessed the noninferiority (defined as a difference of ≤10%) of seroconversion and seroresponse rates to MV, YFV, and MenAV. We compared the seroresponse to PRV. Results: Seroconversion to MV occurred in 255 of 261 PRV recipients (97.7%) and 246 of 252 control infants (97.6%; difference, 0.1% [95% confidence interval {CI}, -4.0%-4.2%]). Seroresponse to YFV occurred in 48.1% of PRV recipients (141 of 293), compared with 52.2% of controls (153 of 293; difference, -4.1% [95% CI, -12.2%-4.0%]). A 4-fold rise in meningococcus A bactericidal titer was observed in 273 of 292 PRV recipients (93.5%) and 276 of 293 controls (94.2%; difference, -0.7% [95% CI, -5.2%-3.8%]). Rises in geometric mean concentrations of immunoglobulin A and immunoglobulin G antibodies to rotavirus were higher among PRV recipients (118 [95% CI, 91-154] and 364 [95% CI, 294-450], respectively), compared with controls (68 [95% CI, 50-92] and 153 [95% CI, 114-207], respectively). Conclusions: PRV did not interfere with MV and MenAV; this study could not rule out interference with YFV. PRV increased serum rotavirus antibody levels. Clinical trials registration: NCT02286895.
In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis

L. Kurlandsky,R. Fader

DOI: https://doi.org/10.1002/(SICI)1099-0496(200003)29:3<210::AID-PPUL9>3.0.CO;2-2

IF: 4.0899

2000-03-01

Pediatric Pulmonology

Abstract:Our objective was to determine the in vitro activity of minocycline against isolates of Burkholderia cepacia (BC), Stenotrophomonas maltophilia (SM), and Pseudomonas aeruginosa (PA) cultured from the respiratory tract of patients with cystic fibrosis (CF). Cultures of BC, SM, and PA were isolated in a hospital bacteriology laboratory from the sputum or oropharyngeal cultures obtained from patients attending a Cystic Fibrosis Center, and were prospectively tested for in vitro sensitivity to minocycline by Kirby‐Bauer disk diffusion.
Rotavirus Vaccine Trials in International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) and Future Use of the Vaccine in Bangladesh

K Zaman,Asma Binte Aziz,Md Yunus,Firdausi Qadri,Allen G Ross,John D Clemens

DOI: https://doi.org/10.1093/infdis/jiab442

2021-09-16

The Journal of Infectious Diseases

Abstract:Abstract Safe and effective rotavirus vaccines (RVs) are needed to reduce the enormous public health burden of rotavirus illness in developing countries. Vaccination is critical for effective control of rotavirus infection since it cannot be prevented with improvements in water and sanitation. The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) has completed several groundbreaking RV trials (Phase I–Phase IV). The safety, immunogenicity, efficacy, and effectiveness of different RVs were evaluated among both urban and rural populations. In this study, we present the results, policy implications, and lessons learned for successful implementation of these trials as well as future directions for rotavirus vaccination in Bangladesh.
Nasal Foreign Body, Dislodged and Lost - Can the Adenoids Help?

Arijit Jotdar,M. Dutta,Subrata Mukhopadhyay

DOI: https://doi.org/10.7860/JCDR/2015/13772.6073

2015-06-01

Abstract:Foreign body in the nasal cavity is one of the most common paediatric otolaryngology emergencies and needs to be promptly addressed. The incidence of nasal foreign body getting dislodged secondary to unsuccessful attempts to take it out is quite high and can be potentially dangerous as it might cause fatal airway compromise. The chances of it getting impacted and retained in the nasopharynx are practical, although such cases are seldom encountered for primarily nasal foreign bodies. Nevertheless, the nasopharynx should always be looked for as a site of impaction of hidden foreign objects. Presence of enlarged adenoids could be of help as it may prevent accidental lodgement of displaced foreign body in the airway, but might also result in difficulty in locating and retrieving the foreign body because it acts as an anchor-pad with its grooves and crevasses. This report presents a rare, interesting case of a child with enlarged adenoids anchoring a metallic ring and describes the clinical presentations and relevant management of a nasal foreign body dislodged and lost in the nasopharynx.
Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi

Benjamin Morgan,Eleanor A. Lyons,Amanda Handley,Nada Bogdanovic-Sakran,Daniel Pavlic,Desiree Witte,Jonathan Mandolo,Ann Turner,Khuzwayo C. Jere,Frances Justice,Darren Suryawijaya Ong,Rhian Bonnici,Karen Boniface,Celeste M. Donato,Ashley Mpakiza,Anell Meyer,Naor Bar-Zeev,Miren Iturriza-Gomara,Nigel A. Cunliffe,Margaret Danchin,Julie E. Bines

DOI: https://doi.org/10.3390/v16091488

2024-09-20

Viruses

Abstract:High titres of rotavirus-specific maternal antibodies may contribute to lower rotavirus vaccine efficacy in low- and middle-income countries (LMICs). RV3-BB vaccine (G3P[6]) is based on a neonatal rotavirus strain that replicates well in the newborn gut in the presence of breast milk. This study investigated the association between maternal serum antibodies and vaccine response in infants administered the RV3-BB vaccine. Serum was collected antenatally from mothers of 561 infants enrolled in the RV3-BB Phase II study conducted in Blantyre, Malawi, and analysed for rotavirus-specific serum IgA and IgG antibodies using enzyme-linked immunosorbent assay. Infant vaccine take was defined as cumulative IgA seroconversion (≥3 fold increase) and/or stool vaccine shedding. Maternal IgA or IgG antibody titres did not have a negative impact on vaccine-like stool shedding at any timepoint. Maternal IgG (but not IgA) titres were associated with reduced take post dose 1 (p < 0.005) and 3 (p < 0.05) in the neonatal vaccine schedule group but not at study completion (week 18). In LMICs where high maternal antibodies are associated with low rotavirus vaccine efficacy, RV3-BB in a neonatal or infant vaccine schedule has the potential to provide protection against severe rotavirus disease.

virology
Human neonatal rotavirus vaccine (RV3-BB) targets rotavirus from birth

Y. Soenarto,A. Handley,H. Nirwati,Karen Boniface,N. Bachtiar,Emma Watts,Daniel Pavlic,Jarir At Thobari,Jane Standish,Katherine J. Lee,R. Bishop,C. Kirkwood,J. Bines,Gabrielle Byars,J. Buttery,D. Cowley,C. D. Satria,G. Barnes,N. Bogdanovic-Sakran,J. Ackland,Ajeng Viska Icanervilia,F. Justice

DOI: https://doi.org/10.1056/NEJMoa1706804

IF: 158.5

2018-02-21

New England Journal of Medicine

Abstract:Background A strategy of administering a neonatal rotavirus vaccine at birth to target early prevention of rotavirus gastroenteritis may address some of the barriers to global implementation of a rotavirus vaccine. Methods We conducted a randomized, double‐blind, placebo‐controlled trial in Indonesia to evaluate the efficacy of an oral human neonatal rotavirus vaccine (RV3‐BB) in preventing rotavirus gastroenteritis. Healthy newborns received three doses of RV3‐BB, administered according to a neonatal schedule (0 to 5 days, 8 weeks, and 14 weeks of age) or an infant schedule (8 weeks, 14 weeks, and 18 weeks of age), or placebo. The primary analysis was conducted in the per‐protocol population, which included only participants who received all four doses of vaccine or placebo within the visit windows, with secondary analyses performed in the intention‐to‐treat population, which included all participants who underwent randomization. Results Among the 1513 participants in the per‐protocol population, severe rotavirus gastroenteritis occurred up to the age of 18 months in 5.6% of the participants in the placebo group (28 of 504 babies), in 1.4% in the neonatal‐schedule vaccine group (7 of 498), and in 2.7% in the infant‐schedule vaccine group (14 of 511). This resulted in a vaccine efficacy of 75% (95% confidence interval [CI], 44 to 91) in the neonatal‐schedule group (P<0.001), 51% (95% CI, 7 to 76) in the infant‐schedule group (P=0.03), and 63% (95% CI, 34 to 80) in the neonatal‐schedule and infant‐schedule groups combined (combined vaccine group) (P<0.001). Similar results were observed in the intention‐to‐treat analysis (1649 participants); the vaccine efficacy was 68% (95% CI, 35 to 86) in the neonatal‐schedule group (P=0.001), 52% (95% CI, 11 to 76) in the infant‐schedule group (P=0.02), and 60% (95% CI, 31 to 76) in the combined vaccine group (P<0.001). Vaccine response, as evidenced by serum immune response or shedding of RV3‐BB in the stool, occurred in 78 of 83 participants (94%) in the neonatal‐schedule group and in 83 of 84 participants (99%) in the infant‐schedule group. The incidence of adverse events was similar across the groups. No episodes of intussusception occurred within the 21‐day risk period after administration of any dose of vaccine or placebo, and one episode of intussusception occurred 114 days after the third dose of vaccine in the infant‐schedule group. Conclusions RV3‐BB was efficacious in preventing severe rotavirus gastroenteritis when administered according to a neonatal or an infant schedule in Indonesia. (Funded by the Bill and Melinda Gates Foundation and others; Australian New Zealand Clinical Trials Registry number, ACTRN12612001282875.)

Medicine
Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial

Zhi-Wei Wu,Fei Jin,Qing-Liang Li,Jia-Mei Gao,Hai-Song Zhou,Kai Duan,Zhao Gao,Yan Liu,Zhi-Yong Hao,Wei Chen,Yue-Yue Liu,Ge-Lin Xu,Biao Yang,Ben Dong,Jiu-Wei Zhang,Yu-Liang Zhao,Xiao-Ming Yang

DOI: https://doi.org/10.1080/21645515.2023.2263228

Abstract:Rotavirus remains a major cause of diarrhea among 5-y-old children, and vaccination is currently the most effective and economical measure. We conducted a randomized, double-blind, placebo-controlled phase II clinical trial designed to determine the dosage, immunogenicity, and safety profile of a novel hexavalent rotavirus vaccine. In total, 480 eligible healthy infants, who were 6-12 weeks of age at the time of randomization were randomly allocated (1:1:1) to receive 105.5 focus-forming unit (FFU) or 106.5FFU of vaccine or placebo on a 0, 28 and 56-d schedule. Blood samples were collected 28 d after the third dose to assess rotavirus immunoglobulin A (IgA) antibody levels. Adverse events (AEs) up to 28 d after each dose and serious adverse events (SAEs) up to 6 months after the third dose were recorded as safety measurements. The anti-rotavirus IgA seroconversion rate of the vaccine groups reached more than 70.00%, ranging from 74.63% to 76.87%. The postdose 3 (PD3) geometric mean concentrations (GMCs) of anti-rotavirus IgA among vaccine recipients ranged from 76.97 U/ml to 84.46 U/ml. At least one solicited AE was recorded in 114 infants (71.25%) in the high-dose vaccine group, 106 infants (66.25%) in the low-dose vaccine group and 104 infants (65.00%) in the placebo group. The most frequently solicited AE was fever. The novel oral hexavalent rotavirus vaccine was safe and immunogenic in infants support the conclusion to advance the candidate vaccine for phase 3 efficacy trials.
[Preparation of leukocyte-poor thrombocyte concentrates from buffy coat by using a new quadruple bag system].

J. Misterek,K. Müller,J. Bux,C. Mueller-Eckhardt

Abstract:It has repeatedly been shown that platelet concentrates (PC) can be prepared from buffy coat in guadruple Saline(S)-Adenin(A)-Glucose(G)-Mannitol(M) (SAG-M) systems. Their in vivo and in vitro quality was reported to be excellent and their contamination with leucocytes was 10-20 times lower than in PC prepared from platelet rich plasma. We have confirmed these observations (unpublished results). One particular technical problem which we encountered was the appearance of folds in the satellite bag during the second centrifugation step rendering the purity of the PC quite unpredictable. In collaboration with Biotrans, we have developed a modified quadruple bag (733861100) including a special insert (Heraeus Christ, Osterode, FRG) for the centrifugation rotor which has proved advantageous over existing systems and will be briefly described.
Quantifying the Impact of Natural Immunity on Rotavirus Vaccine Efficacy Estimates: A Clinical Trial in Dhaka, Bangladesh (PROVIDE) and a Simulation Study

Elizabeth T Rogawski,James A Platts-Mills,E Ross Colgate,Rashidul Haque,K Zaman,William A Petri,Beth D Kirkpatrick

DOI: https://doi.org/10.1093/infdis/jix668

2018-01-31

The Journal of Infectious Diseases

Abstract:Background: The low efficacy of rotavirus vaccines in clinical trials performed in low-resource settings may be partially explained by acquired immunity from natural exposure, especially in settings with high disease incidence.Methods: In a clinical trial of monovalent rotavirus vaccine in Bangladesh, we compared the original per-protocol efficacy estimate to efficacy derived from a recurrent events survival model in which children were considered naturally exposed and potentially immune after their first rotavirus diarrhea (RVD) episode. We then simulated trial cohorts to estimate the expected impact of prior exposure on efficacy estimates for varying rotavirus incidence rates and vaccine efficacies.Results: Accounting for natural immunity increased the per-protocol vaccine efficacy estimate against severe RVD from 63.1% (95% confidence interval [CI], 33.0%-79.7%) to 70.2% (95% CI, 44.5%-84.0%) in the postvaccination period, and original year 2 efficacy was underestimated by 14%. The simulations demonstrated that this expected impact increases linearly with RVD incidence, will be greatest for vaccine efficacies near 50%, and can reach 20% in settings with high incidence and low efficacy.Conclusions: High rotavirus incidence leads to predictably lower vaccine efficacy estimates due to the acquisition of natural immunity in unvaccinated children, and this phenomenon should be considered when comparing efficacy estimates across settings.Clinical Trials Registration: NCT01375647.

immunology,infectious diseases,microbiology
Oral rotavirus vaccine shedding as a marker of mucosal immunity

Benjamin Lee,Md Abdul Kader,E. Ross Colgate,Marya Carmolli,Dorothy M. Dickson,Sean A. Diehl,Masud Alam,Sajia Afreen,Josyf C. Mychaleckyj,Uma Nayak,William A. Petri,Rashidul Haque,Beth D. Kirkpatrick

DOI: https://doi.org/10.1038/s41598-021-01288-1

IF: 4.6

2021-11-05

Scientific Reports

Abstract:Abstract Group A rotaviruses (RVA) remain a leading cause of pediatric diarrhea worldwide, in part due to underperformance of currently approved live-attenuated, oral vaccines in low-and-middle income countries. Improved immune correlates of protection (CoP) for existing oral vaccines and novel strategies to evaluate the performance of next-generation vaccines are needed. Use of oral vaccines as challenge agents in controlled human infection models is a potential approach to CoP discovery that remains underexplored. In a live-attenuated, oral rotavirus vaccine (Rotarix, GlaxoSmithKline) efficacy trial conducted among infants in Dhaka, Bangladesh, we explored the potential for the second dose of the two-dose series to be considered a challenge agent through which RVA immunity could be explored, using fecal virus shedding post-dose 2 as a marker of mucosal immunity. Among 180 vaccinated infants who completed the parent study per protocol, the absence of fecal vaccine shedding following the second dose of Rotarix suggested intestinal mucosal immunity generated by the first dose and a decreased risk of RVA diarrhea through 2 years of life (RR 0.616, 95% CI 0.392–0.968). Further development of controlled human infection models for group A rotaviruses, especially in prospective studies with larger sample sizes, may be a promising tool to assess rotavirus vaccine efficacy and CoPs.

multidisciplinary sciences
A qualitative assessment of factors influencing acceptance of a new rotavirus vaccine among health care providers and consumers

Manish M Patel,Alan P Janssen,Richard R Tardif,Mark Herring,Umesh D Parashar

DOI: https://doi.org/10.1186/1471-2431-7-32

2007-10-18

BMC Pediatrics

Abstract:BackgroundIn 2006, a new rotavirus vaccine (RotaTeq) was licensed in the US and recommended for routine immunization of all US infants. Because a previously licensed vaccine (Rotashield) was withdrawn from the US for safety concerns, identifying barriers to uptake of RotaTeq will help develop strategies to broaden vaccine coverage.MethodsWe explored beliefs and attitudes of parents (n = 57) and providers (n = 10) towards rotavirus disease and vaccines through a qualitative assessment using focus groups and in-depth interviews.ResultsAll physicians were familiar with safety concerns about rotavirus vaccines, but felt reassured by RotaTeq's safety profile. When asked about likelihood of using RotaTeq on a scale of one to seven (1 = "absolutely not;" 7 = "absolutely yes") the mean score was 5 (range = 3–6). Physicians expressed a high likelihood of adopting RotaTeq, particularly if recommended by their professional organizations and expressed specific interest in post-marketing safety data. Similarly, consumers found the RotaTeq safety profile to be favorable and would rely on their physician's recommendation for vaccination. However, when asked to rank likelihood of having their child vaccinated against rotavirus (1 = "definitely not get;" 7 = "definitely get"), 29% ranked 1 or 2, 36% 3 or 4, and 35% 5 to 7.ConclusionOur qualitative assessment provides complementary data to recent quantitative surveys and suggests that physicians and parents are likely to adopt the newly licensed rotavirus vaccine. Increasing parental awareness of the rotavirus disease burden and providing physicians with timely post-marketing surveillance data will be integral to a successful vaccination program.

pediatrics
The impact of rotavirus vaccination on acute diarrhea in Thai children under 5 years of age in the first year of universal implementation of rotavirus vaccines in the National Immunization Program (NIP) in Thailand: a 6-year analysis

Busara Charoenwat,Kunanya Suwannaying,Watuhatai Paibool,Napat Laoaroon,Sumitr Sutra,Kaewjai Thepsuthammarat,Suphasarang Sirirattanakul

DOI: https://doi.org/10.1186/s12889-023-16958-0

IF: 4.5

2023-10-27

BMC Public Health

Abstract:Background: Two types of rotavirus vaccines (RVs), Rotarix (RV1) and RotaTeq (RV5), were licensed as optional vaccines in 2012 and became part of the National Immunization Program (NIP) in the fiscal year 2020 in Thailand. The main objective was to evaluate the impact of rotavirus vaccines on the burden of acute diarrheal severity ranging from outpatient visits, diarrheal-related admission or deaths in the pre-NIP period (fiscal year 2015-2019) and in the fiscal year 2020. The minor objectives were assessed on the monthly admission rate, rotavirus vaccine coverage rate and rotavirus vaccine completed dose (RotaC). Methods: Data regarding OPD, admission, and death cases under the Thailand National Health Coverage (NHC) from fiscal year 2015-2020, which were recorded as International Classification of Diseases and Related Health Problem 10th (ICD-10), were analyzed. Results: The burden of diarrheal-related disease diminished after the rotavirus vaccine was introduced in the fiscal year 2020 when compared to the previous 5 fiscal years. The OPD visit rate decreased from 10.1 to 8.3 visits per 100 person-years (P < 0.001), or a 17.8% reduction (incidence rate ratio (IRR) = 0.82; 95% confidence interval (CI): 0.81 to 0.82). The admission rate significantly declined from 31.4 to 30.5 cases per 1,000 person-years, (P < 0.001), or a 2.9% reduction (IRR = 0.97; 95% CI: 0.96 to 0.98). The diarrheal-related mortality rate also subsided from 10.2 to 8.1 cases per 100,000 person-years (P 0.3), or a 20.0% reduction (IRR = 0.88; 95% CI: 0.50 to 1.22). The major population in both admissions and deaths was infants under 1 year of age (P < 0.001). Seasonality was seen as a constant bimodal pattern, with a significant decrease in monthly admissions after 6 months of rotavirus vaccine introduction to NIP (P < 0.001). RotaC was 37.4% in the first year of NIP. Conclusions: The rotavirus vaccine had a potential benefit for reducing the diarrheal disease burden, especially in infants under one year of age. Seasonality outbreaks of acute diarrhea subsided after the rotavirus vaccine was introduced. The RotaC was fairly low in the first year of the NIP. The quality of the rotavirus vaccine should be warranted. Trial registration: Number TCTR20220120003 , date of registration: 20/01/2022, site: Thai Clinical Trials Registry.
Regional myocardial ischemia in hypertrophic cardiomyopathy: impact of myectomy.

Manuela Jörg-Ciopor,M. Namdar,J. Turina,R. Jenni,J. Schwitter,M. Turina,O. Hess,P. Kaufmann

DOI: https://doi.org/10.1016/J.JTCVS.2003.11.003

IF: 6.439

2004-08-01

Journal of Thoracic and Cardiovascular Surgery

Abstract:

Biplane US-Guided Real-Time Volumetric Target Pose Estimation Method for Theragnostic HIFU System

Safety and immunogenicity of the Rotavac and Rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants: a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial

Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial

Angiographically occult vascular malformations in childhood.

Immunogenicity of pentavalent rotavirus vaccine in Chinese infants

Treatment refusal in anorexia nervosa.

Immunogenicity of RV1 and RV5 vaccines administered in standard and interchangeable mixed schedules: a randomized, double-blind, non-inferiority clinical trial in Mexican infants

Association of Rotavirus Vaccines With Reduction in Rotavirus Gastroenteritis in Children Younger Than 5 Years

Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Coadministered With Measles, Yellow Fever, and Meningitis A Vaccines in 9-Month-Old Malian Infants

In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis

Rotavirus Vaccine Trials in International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) and Future Use of the Vaccine in Bangladesh

Nasal Foreign Body, Dislodged and Lost - Can the Adenoids Help?

Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi

Human neonatal rotavirus vaccine (RV3-BB) targets rotavirus from birth

Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial

[Preparation of leukocyte-poor thrombocyte concentrates from buffy coat by using a new quadruple bag system].

Quantifying the Impact of Natural Immunity on Rotavirus Vaccine Efficacy Estimates: A Clinical Trial in Dhaka, Bangladesh (PROVIDE) and a Simulation Study

Oral rotavirus vaccine shedding as a marker of mucosal immunity

A qualitative assessment of factors influencing acceptance of a new rotavirus vaccine among health care providers and consumers

The impact of rotavirus vaccination on acute diarrhea in Thai children under 5 years of age in the first year of universal implementation of rotavirus vaccines in the National Immunization Program (NIP) in Thailand: a 6-year analysis

Regional myocardial ischemia in hypertrophic cardiomyopathy: impact of myectomy.